Findings

What do systematic reviews say?

256 questions · 278 findings · 34 reviews · ENT

Sort:Best matchNewest Highest certainty Download CSV

No studies found 86 · 30.9%GRADE not reported 1 · 0.4%Very low 88 · 31.7%Low 66 · 23.7%Moderate 35 · 12.6%High 2 · 0.7%

Specially processed cereals vs placebo

Improvement in vertigo · Ménière’s disease

The review found no eligible studies for this question.

1 finding from 1 review

Lifestyle and dietary interventions for Ménière’s disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Specially processed cereals vs placebo

Change in vertigo · Ménière’s disease

The review found no eligible studies for this question.

1 finding from 1 review

Lifestyle and dietary interventions for Ménière’s disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Specially processed cereals vs placebo

Serious adverse events · Ménière’s disease

The review found no eligible studies for this question.

1 finding from 1 review

Lifestyle and dietary interventions for Ménière’s disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intratympanic corticosteroids vs placebo/no treatment

Improvement in vertigo frequency · Ménière’s disease

Intratympanic corticosteroids showed no clear difference in improvement in vertigo frequency compared with placebo/no treatment (low certainty).

2 findings from 1 review

Intratympanic corticosteroids for Ménière’s disease 2023 · Cochrane Headline outcomes only
RR 1 [0.92, 1.1]
2 studies · 60 participants
Low
Intratympanic corticosteroids for Ménière’s disease 2023 · Cochrane Headline outcomes only
RR 1.03 [0.87, 1.23]
2 studies · 58 participants
Low

Intratympanic corticosteroids vs placebo/no treatment

Change in vertigo (global score) · Ménière’s disease

1 finding from 1 review

Intratympanic corticosteroids for Ménière’s disease 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 44 participants
Very low

Intratympanic corticosteroids vs placebo/no treatment

Change in vertigo frequency · Ménière’s disease

3 findings from 1 review

Intratympanic corticosteroids for Ménière’s disease 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 472 participants
Low
Intratympanic corticosteroids for Ménière’s disease 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 20 participants
Very low
Intratympanic corticosteroids for Ménière’s disease 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 18 participants
Very low

Intratympanic corticosteroids vs placebo/no treatment

Serious adverse events · Ménière’s disease

It is very uncertain whether intratympanic corticosteroids changes serious adverse events compared with placebo/no treatment (very low certainty).

1 finding from 1 review

Intratympanic corticosteroids for Ménière’s disease 2023 · Cochrane Headline outcomes only
RR 0.64 [0.22, 1.85]
4 studies · 500 participants
Very low

Intratympanic gentamicin vs no treatment/placebo

Improvement in vertigo frequency · Ménière’s disease

It is very uncertain whether intratympanic gentamicin changes improvement in vertigo frequency compared with no treatment/placebo (very low certainty).

2 findings from 1 review

Intratympanic gentamicin for Ménière’s disease 2023 · Cochrane Headline outcomes only
RR 33 [2.15, 507]
1 study · 32 participants
Very low
Intratympanic gentamicin for Ménière’s disease 2023 · Cochrane Headline outcomes only
RR 1.63 [0.98, 2.69]
1 study · 22 participants
Very low

Intratympanic gentamicin vs no treatment/placebo

Vertigo (global score) at < 3 months · Ménière’s disease

2 findings from 1 review

Intratympanic gentamicin for Ménière’s disease 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 26 participants
Very low
Intratympanic gentamicin for Ménière’s disease 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 26 participants
Very low

Intratympanic gentamicin vs no treatment/placebo

Vertigo (frequency) · Ménière’s disease

1 finding from 1 review

Intratympanic gentamicin for Ménière’s disease 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Very low

Intratympanic gentamicin vs no treatment/placebo

Serious adverse events · Ménière’s disease

The review found no eligible studies for this question.

1 finding from 1 review

Intratympanic gentamicin for Ménière’s disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Positive pressure therapy vs placebo

Improvement in vertigo frequency · Ménière’s disease

Positive pressure therapy showed no clear difference in improvement in vertigo frequency compared with placebo (low certainty).

1 finding from 1 review

Positive pressure therapy for Ménière’s disease 2023 · Cochrane Headline outcomes only
RR 1.19 [0.82, 1.71]
1 study · 77 participants
Low

Positive pressure therapy vs placebo

Change in vertigo (global score) · Ménière’s disease

1 finding from 1 review

Positive pressure therapy for Ménière’s disease 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 68 participants
Very low

Positive pressure therapy vs placebo

Change in vertigo frequency · Ménière’s disease

1 finding from 1 review

Positive pressure therapy for Ménière’s disease 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 202 participants
Very low

Positive pressure therapy vs placebo

Serious adverse events · Ménière’s disease

The review found no eligible studies for this question.

1 finding from 1 review

Positive pressure therapy for Ménière’s disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Endolymphatic sac decompression vs placebo (sham surgery)

Improvement in vertigo (complete resolution) at 6 to ≤ 12 months (12 months) · Ménière’s disease

It is very uncertain whether endolymphatic sac decompression changes improvement in vertigo (complete resolution) at 6 to ≤ 12 months (12… compared with placebo (sham surgery) (very low certainty).

1 finding from 1 review

Surgical interventions for Ménière’s disease 2023 · Cochrane Headline outcomes only
RR 1.3 [0.86, 1.96]
1 study · 30 participants
Very low

Endolymphatic sac decompression vs placebo (sham surgery)

Improvement in vertigo · Ménière’s disease

1 finding from 1 review

Surgical interventions for Ménière’s disease 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 29 participants
Very low

Endolymphatic sac decompression vs placebo (sham surgery)

Serious adverse events · Ménière’s disease

The review found no eligible studies for this question.

1 finding from 1 review

Surgical interventions for Ménière’s disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Antibiotics vs placebo

Hearing ‐ return to normal *Ventilation tubes versus laser myringotomy (6 to 12 months ‐ medium‐term) Adjusted for non‐independence of within‐individual measurements Assumed ICC of 0.5 № of participants: 132 (2 RCTs) · children aged 6 months to 12 years with otitis media with effusion (OME)

It is very uncertain whether antibiotics changes hearing ‐ return to normal hearing (as complete improvement in… compared with placebo (very low certainty).

1 finding from 1 review

Antibiotics for otitis media with effusion (OME) in children 2023 · Cochrane Headline outcomes only
Peto OR 9.59 [3.51, 26.18]
Studies not reported
Very low

Antibiotics vs placebo

Disease‐specific quality of life · children aged 6 months to 12 years with otitis media with effusion (OME)

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotics for otitis media with effusion (OME) in children 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found